Annals of Surgical Oncology

, Volume 10, Issue 8, pp 852–862 | Cite as

Overcoming Antiapoptotic Responses to Promote Chemosensitivity in Metastatic Colorectal Cancer to the Liver

  • James C. CusackJr.Email author
New Approaches to the Treatment of Hepatic Malignancies


Background: Metastatic colon cancer is highly resistant to chemotherapy. A variety of mechanisms by which cancer cells resist chemotherapy have been described including enhanced export of drug from cancer cells and alterations in drug metabolism. In addition, the response of cancer cells to genotoxic therapies may be diminished by acquired defects in either the response mechanisms to DNA damage or cell cycle regulatory pathways. Recently, attention has focused on mechanisms that are activated by treatment exposure and subsequently promote resistance by rescuing cancer cells from apoptosis. The objective of this review is to examine the role of antiapoptotic mechanisms of chemotherapy resistance and to determine the potential utility of therapeutic strategies that target these mechanisms.

Methods: To accomplish the objectives, a brief overview of mechanisms of chemotherapy resistance is provided. The concept of inducible chemotherapy resistance is introduced by examination of a specific antiapoptotic mechanism, mediated by the transcription factor, nuclear factor kappa B (NF-κB). The ability to use inhibitors of NF-κB to promote chemosensitivity is examined in vitro and in vivo.

Results: Inhibition of chemotherapy-induced NF-κB activation enhances apoptosis and augments chemotherapy sensitivity.

Conclusions: NF-κB inhibition may overcome cancer cell defense against apoptosis. Molecular therapies that target this resistance mechanism may be useful adjuncts to conventional chemotherapy.

Key Words

Chemotherapy resistance Apoptosis NF-κB Colon cancer Liver metastases 


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Hickman JA. Apoptosis induced by anticancer drugs. Cancer Metastasis Rev 1992;11:121–39.CrossRefPubMedGoogle Scholar
  2. 2.
    Kerr JF, Winterford CM, Harmon BV. Apoptosis. Its significance in cancer and cancer therapy. Cancer 1994;73:2013–26.CrossRefPubMedGoogle Scholar
  3. 3.
    Steller H. Mechanisms and genes of cellular suicide. Science 1995;267:1445–9.CrossRefPubMedGoogle Scholar
  4. 4.
    Cunningham D. Current status of colorectal cancer: CPT-11 (irinotecan), a therapeutic innovation. Eur J Cancer 1996;32A:S1.CrossRefPubMedGoogle Scholar
  5. 5.
    Schmitt CA, Lowe SW. Apoptosis and therapy. J Pathol 1999;187:127–37.CrossRefPubMedGoogle Scholar
  6. 6.
    Wu GS, El-Deiry WS. Apoptotic death of tumor cells correlates with chemosensitivity, independent of p53 or bcl-2. Clin Cancer Res 1996;2:623–33.PubMedGoogle Scholar
  7. 7.
    Kastan MB. Molecular determinants of sensitivity to antitumor agents. Biochim Biophys Acta 1999;1424:R37–42.PubMedGoogle Scholar
  8. 8.
    El-Deiry WS. Role of oncogenes in resistance and killing by cancer therapeutic agents. Curr Opin Oncol 1997;9:79–87.CrossRefPubMedGoogle Scholar
  9. 9.
    Baldini N. Multi-drug resistance - a multiplex phenomenon. Nat Med 1997;3:378–80.CrossRefPubMedGoogle Scholar
  10. 10.
    Fisher DE. Apoptosis in cancer therapy: crossing the threshold. Cell 1996;78:539–42.CrossRefGoogle Scholar
  11. 11.
    Friesen C, Herr I, Krammer PH, Debatin KM. Involvement of the CD95 (APO-1/FAS) receptor/ligand system in drug-induced apoptosis in leukemia cells. Nat Med 1996;2:574–7.CrossRefPubMedGoogle Scholar
  12. 12.
    Fulda S, Susin SA, Kroemer G, Debatin KM. Molecular ordering of apoptosis induced by anticancer drugs in neuroblastoma cells. Cancer Res 1998;58:4453–60.PubMedGoogle Scholar
  13. 13.
    Kirsch DG, Kastan MB. Tumor-suppressor p53: implications for tumor development and prognosis. J Clin Oncol 1998;16:3158–68.CrossRefPubMedGoogle Scholar
  14. 14.
    Sikic BI, Fisher GA, Lum BL, Halsey J, Beketic-Oreskovic L, Chen G. Modulation and prevention of multidrug resistance by inhibitors of P-glycoprotein. Cancer Chemother Pharmacol 1997;40:S13–9.CrossRefPubMedGoogle Scholar
  15. 15.
    Shi MM, Bleavins MR, de la Iglesia FA. Technologies for detecting genetic polymorphisms in pharamacogenics. Mol Diagn 1999;4:343–51.CrossRefPubMedGoogle Scholar
  16. 16.
    Kivisto KT, Kroemer HK, Eichelbaum M. The role of human cytochrome P450 enzymes in the metabolism of anticancer agents: implications for drug interactions. Br J Clin Pharmaco 1995;40:523.CrossRefGoogle Scholar
  17. 17.
    De Angelis P, Stokke T, Smedshammer L, et al. P-glycoprotein is not expressed in a majority of colorectal carcinomas and is not regulated by mutant p53 in vivo. Br J Cancer 1995;72:307–11.CrossRefPubMedCentralPubMedGoogle Scholar
  18. 18.
    Sinha P, Hutter G, Kottgen E, Dietel M, Schadendorf D, Lage H. Search for novel proteins involved in the development of chemoresistance in colorectal cancer and fibrosarcoma cells in vitro using two-dimensional electrophoresis, mass spectrometry, and microsequencing. Electrophoresis 1999;20:2961–9.CrossRefPubMedGoogle Scholar
  19. 19.
    Mini E, Biondi C, Morganti M, et al. Marked variation of thymidylate synthase and folylpolyglutamate synthetase gene expression in human colorectal tumors. Oncol Res 1999;11:437–45.PubMedGoogle Scholar
  20. 20.
    Kerr JF, Wyllie AH, Currie AR. Apoptosis: a basic biological phenomenon with wide-ranging implications in tissue kinetics. Br J Cancer 1972;26:239–57.CrossRefPubMedCentralPubMedGoogle Scholar
  21. 21.
    Vogelstein B, Fearon ER, Hamilton SR, et al. Genetic alterations during colorectal-tumor development. N Engl J Med 1988;319:525–32.CrossRefPubMedGoogle Scholar
  22. 22.
    Fearon ER, Vogelstein B. A genetic model for colorectal tumorigenesis. Cell 1990;61:759–67.CrossRefPubMedGoogle Scholar
  23. 23.
    Grasl-Kraupp B, Ruttkay-Nedecky B, Mullauer L, et al. Inherent increase of apoptosis in liver tumors: implications for carcinogenesis and tumor regression. Hepatology 1997;25:906–12.CrossRefPubMedGoogle Scholar
  24. 24.
    Dixon SC, Soriano BJ, Lush RM, Borner MM, Figg WD. Apoptosis: its role in the development of malignancies and its potential as a novel therapeutic target. Ann Pharmacother 1997;31:76.CrossRefPubMedGoogle Scholar
  25. 25.
    Bellamy CO, Clarke AR, Wyllie AH, Harrison DJ. p53 deficiency in liver reduces local control of survival and proliferation, but does not affect apoptosis after DNA damage. Faseb J 1997;11:591–9.CrossRefPubMedGoogle Scholar
  26. 26.
    Soini Y, Virkajarvi N, Lehto VP, Paakko P. Hepatocellular carcinomas with a high proliferation index and a low degree of apoptosis and necrosis are associated with a shortened survival. Br J Cancer 1996;73:1025–30.CrossRefPubMedCentralPubMedGoogle Scholar
  27. 27.
    Levine AJ. p53, the cellular gatekeeper for growth and division. Cell 1997;88:323–31.CrossRefPubMedGoogle Scholar
  28. 28.
    Polyak K, Xia Y, Zweier JL, et al. A model for p53-induced apoptosis. Nature 1997;389:300–5.CrossRefPubMedGoogle Scholar
  29. 29.
    Symonds H, Krall L, Remington L, et al. p-53 dependent apoptosis suppresses tumor growth and progression in vivo. Cell 1994;78:703–11.CrossRefPubMedGoogle Scholar
  30. 30.
    Roth JA, Cristiano RJ. Gene therapy for cancer: what have we done and where are we going? J Natl Cancer Institute 1997;89:21–39.CrossRefGoogle Scholar
  31. 31.
    Friedman SL, Shaulian E, Littlewood T, et al. Resistance to p53-mediated growth arrest and apoptosis in Hep 3B hepatoma cells. Oncogene 1997;15:63–70.CrossRefPubMedGoogle Scholar
  32. 32.
    Wang C-Y, Mayo M, Baldwin ASJ. TNF- and cancer therapy-induced apoptosis: potentiation by inhibition of NF-kB. Science 1996;274:784–7.CrossRefPubMedGoogle Scholar
  33. 33.
    Beg AA, Baltimore D. An essential role for NF-kB in preventing TNF-alpha-induced cell death. Science 1996;274:782.CrossRefPubMedGoogle Scholar
  34. 34.
    Liu ZG, Hsu H, Goeddel DV, Karin M. Dissection of TNF receptor 1 effector functions: JNK activation is not linked to apoptosis while NF-kB activation prevents cell death. Cel 1996;87:565.CrossRefGoogle Scholar
  35. 35.
    Van Antwerp DJ, Martin SJ, Kafri T, Green DR, Verma IM. Suppression of TNF-alpha-induced apoptosis by NF-kB. Science 1996;274:787.CrossRefPubMedGoogle Scholar
  36. 36.
    Wang C-Y, Mayo M, Korneluk RG, Goeddel DV, Baldwin ASJ. NF-kB antiapoptosis: induction of TRAF1 and TRAF2 and c-IAP1 and c-IAP2 to suppress caspase-8 activation. Science 1998;281:1680–3.CrossRefPubMedGoogle Scholar
  37. 37.
    Hsu H, Huang J, Shu HB, Baichwal V, Goeddel DV. TNF-dependent recruitment of the protein kinase RIP to the TNF receptor-1 signaling complex. Immunity 1996;4:387–96.CrossRefPubMedGoogle Scholar
  38. 38.
    Hsu H, Xiong J, Goeddel DV. The TNF receptor 1-associated protein TRADD signals cell death and NF-kB activation. Cell 1995;81:495–504.CrossRefPubMedGoogle Scholar
  39. 39.
    Santana P, Pena LA, Haimovitz-Friedman A, et al. Acid sphingomyelinase-deficient human lymphoblasts and mice are defective in radiation-induced apoptosis. Cell 1996;86:189–99.CrossRefPubMedGoogle Scholar
  40. 40.
    Tartaglia LA, Goeddel DV. Two TNF receptors. Immunol Today 1992;13:151–3.CrossRefPubMedGoogle Scholar
  41. 41.
    Wang C-Y, Cusack JC, Liu R, Baldwin ASJ. Control of inducible chemoresistance: enhanced antitumor efficacy via increased apoptosis by inhibition of NF-kB. Nat Med 1999;5:412–7.CrossRefPubMedGoogle Scholar
  42. 42.
    Cusack JC, Wang C-Y, Liu R, Baldwin ASJ. Chemosensitization of human fibrosarcoma xenografts following adenoviral-mediated transfer of the NF-kB super-repressor IkBa gene. Cancer Gene Therapy 1997;4:S44.Google Scholar
  43. 43.
    Cusack JC, Wang C-Y, Liu R, Baldwin ASJ. Chemosensitization of colorectal cancer cells by expression of the NF-kB super-repressor IkBa. Surg Forum 1997;48:815–7.Google Scholar
  44. 44.
    Wang W, Abbruzzese JL, Evans DB, Larry L, Cleary KR, Chiao PJ. The nuclear factor-kB RelA transcription factor is constitutively activated in human pancreatic adenocarcinoma cells. Clin Cancer Res 1999;5:119–27.PubMedGoogle Scholar
  45. 45.
    Orlowski RZ. The role of the ubiquitin-proteasome pathway in apoptosis. Cell Death Differ 1999;6:303–13.CrossRefPubMedGoogle Scholar
  46. 46.
    Mitsiades CS, Treon SP, Mitsiades N, et al. TRAIL/Apo2L ligand selectively induces apoptosis and overcomes drug resistance in multiple myeloma: therapeutic applications. Blood 2001;98:795–804.CrossRefPubMedGoogle Scholar
  47. 47.
    Adams J, Palombella VJ, Elliott PJ, et al. Proteasome inhibitors: a novel class of potent and effective antitumor agents. Cancer Res 1999;59:2615–22.PubMedGoogle Scholar
  48. 48.
    Orlowski RZ, Eswara JR, Lafond-Walker A, Grever MR, Orlowski M, Dang CV. Tumor growth inhibition induced in a murine model of human Burkitt’s lymphoma by a proteasome inhibitor. Cancer Res 1998;58:4342–8.PubMedGoogle Scholar
  49. 49.
    Coux O, Tanaka K, Goldberg AL. Structure and functions of the 20S and 26S proteasomes. Annu Rev Biochem 1996;65:801–47.CrossRefPubMedGoogle Scholar
  50. 50.
    Goldberg AL, Stein R, Adams J. New insights into proteasome function: from archaebacteria to drug development. Chem Biol 1995;2:503–8.CrossRefPubMedGoogle Scholar
  51. 51.
    King RW, Deshaies RJ, Peters JM, Kirschner MW. How proteolysis drives the cell cycle. Science 1996;274:1652–9.CrossRefPubMedGoogle Scholar
  52. 52.
    Grisham MB, Palombella VJ, Elliott PJ, et al. Inhibition of NF-kB activation in vitro and in vivo: role of 26S proteasome. Methods Enzymol 1999;300:345–63.CrossRefPubMedGoogle Scholar
  53. 53.
    Cusack JC, Liu R, Baldwin ASJ. Inducible chemoresistance to 7-ethyl-10-(4-(1-piperidino)-1-piperidino)-carbonyloxycamptothe cin (CPT-11) in colorectal cancer cells and a xenograft model is overcome by inhibition of nuclear factor-kB activation. Cancer Res 2000;60:2323–30.PubMedGoogle Scholar
  54. 54.
    Cusack JC, Liu R, Houston MA, et al. Enhanced chemosensitivity to CPT-11 with proteasome inhibitor PS-341: implications for systemic NF-kB Inhibition. Cancer Res 2001;61:3535–40.PubMedGoogle Scholar
  55. 55.
    Desai SD, Liu LF, Vazquez-Abad D, D’Arpa P. Ubiquitin-dependent destruction of topoisomerase I is stimulated by the antitumor drug camptothecin. J Biol Chem 1997;272:24159–64.CrossRefPubMedGoogle Scholar

Copyright information

© The Society of Surgical Oncology, Inc. 2003

Authors and Affiliations

  1. 1.Division of Surgical OncologyMassachusetts General HospitalBoston
  2. 2.Division of Surgical OncologyMassachusetts General HospitalBoston

Personalised recommendations